BR112014009506A2 - composição médica de eperisona estabilizada e preparação estabilizada de liberação sustentada contendo eperisona - Google Patents

composição médica de eperisona estabilizada e preparação estabilizada de liberação sustentada contendo eperisona

Info

Publication number
BR112014009506A2
BR112014009506A2 BR112014009506A BR112014009506A BR112014009506A2 BR 112014009506 A2 BR112014009506 A2 BR 112014009506A2 BR 112014009506 A BR112014009506 A BR 112014009506A BR 112014009506 A BR112014009506 A BR 112014009506A BR 112014009506 A2 BR112014009506 A2 BR 112014009506A2
Authority
BR
Brazil
Prior art keywords
eperisone
stabilized
preparation containing
medical composition
sustained release
Prior art date
Application number
BR112014009506A
Other languages
English (en)
Other versions
BR112014009506B1 (pt
Inventor
Lee Chang-Kyoo
Park Sang-Geun
Original Assignee
Navipharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navipharm Co Ltd filed Critical Navipharm Co Ltd
Publication of BR112014009506A2 publication Critical patent/BR112014009506A2/pt
Publication of BR112014009506B1 publication Critical patent/BR112014009506B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “composição médica de eperisona estabilizada e preparação estabilizada de liberação sustentada contendo eperisona” a presente invenção refere-se a uma composição médica de eperisona estabilizada, e uma preparação de liberação sustentada contendo a mesma. mais particularmente, a presente invenção refere-se a uma composição médica de eperisona estabilizada que consiste de um sal de eperisona e um oxidante, como ingredientes eficazes, para manter, assim, a estabilidade química dos ingredientes ativos durante o tempo de permanência da droga no corpo, bem como o armazenamento de produtos acabados, e também diz respeito a uma preparação de liberação sustentada contendo a eperisona estabilizada que exibe características de liberação dupla de liberação lenta e rápida, porque a preparação compreende ainda um retardador de liberação em adição à eperisona e ao oxidante.
BR112014009506A 2011-10-18 2012-03-28 preparação estabilizada de liberação sustentada contendo eperisona BR112014009506B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110106388A KR101156054B1 (ko) 2011-09-05 2011-10-18 안정한 에페리손 함유 서방성 의약조성물
PCT/KR2012/002288 WO2013058450A1 (ko) 2011-10-18 2012-03-28 안정화된 에페리손 의약 조성물 및 이를 함유하는 서방성 제제

Publications (2)

Publication Number Publication Date
BR112014009506A2 true BR112014009506A2 (pt) 2017-05-09
BR112014009506B1 BR112014009506B1 (pt) 2020-04-07

Family

ID=48141658

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009506A BR112014009506B1 (pt) 2011-10-18 2012-03-28 preparação estabilizada de liberação sustentada contendo eperisona

Country Status (6)

Country Link
JP (1) JP5948648B2 (pt)
KR (1) KR101156054B1 (pt)
CN (1) CN103889455B (pt)
BR (1) BR112014009506B1 (pt)
MX (1) MX346661B (pt)
WO (1) WO2013058450A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (ko) 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
KR101832842B1 (ko) * 2012-01-13 2018-02-27 한미약품 주식회사 안정성이 향상된 에페리손 또는 이의 약학적으로 허용 가능한 염 및 특정 산성화제를 포함하는 약학 조성물
KR101497354B1 (ko) * 2013-03-29 2015-03-02 초당약품공업 주식회사 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물
KR20140118410A (ko) * 2013-03-29 2014-10-08 초당약품공업 주식회사 저장 및 pH 안정성이 개선된 에페리손 의약 조성물
KR101760278B1 (ko) 2016-08-29 2017-07-21 초당약품공업 주식회사 에페리손을 유효 성분으로 함유하는 서방성 미립구의 제조방법
WO2018044020A1 (ko) * 2016-08-29 2018-03-08 초당약품공업 주식회사 에페리손 서방성 미립구의 제조방법 및 에페리손 서방성 미립구와 아세클로페낙 복합제제
KR101799321B1 (ko) 2016-08-29 2017-11-20 초당약품공업 주식회사 에페리손 서방성 미립구와 아세클로페낙 복합제제
KR102254307B1 (ko) 2019-04-03 2021-05-21 위더스제약주식회사 보관 안정성이 향상된 에페리손 약제학적 조성물
KR102444073B1 (ko) * 2020-01-06 2022-09-16 (주)휴온스 안정성이 향상된 메틸에르고메트린말레산염 함유 약제학적 제제 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0163199B1 (ko) * 1990-05-24 1998-12-01 다이도 나오가따 서방성 좌제
JP3525225B2 (ja) * 1992-11-09 2004-05-10 積水化学工業株式会社 エペリゾンまたはトルペリゾン経皮吸収テープ剤またはパッチ剤、およびその製造方法
US6692769B1 (en) 1998-10-26 2004-02-17 Tanabe Seiyaku Co., Ltd. Sustained-release particles
JP2000143510A (ja) * 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
DE102005014080B4 (de) * 2005-03-21 2007-11-22 Birds Pharma Gmbh Berolina Innovative Research & Development Services Additionssalze des Tolperison, Verfahren zu deren Herstellung, Verwendung derselben und diese enthaltende Arzneimittel
MX2008012264A (es) * 2006-03-24 2009-02-20 Auxilium Int Holdings Inc Composiciones estabilizadas que contienen farmacos labiles alcalinos.
AT505225A1 (de) * 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
EA201171109A1 (ru) * 2009-03-09 2012-03-30 Динеш Шантилал Пател Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия

Also Published As

Publication number Publication date
CN103889455A (zh) 2014-06-25
MX2014004652A (es) 2015-03-05
JP5948648B2 (ja) 2016-07-06
JP2014530250A (ja) 2014-11-17
KR101156054B1 (ko) 2012-06-20
BR112014009506B1 (pt) 2020-04-07
CN103889455B (zh) 2017-12-05
WO2013058450A1 (ko) 2013-04-25
MX346661B (es) 2017-03-28

Similar Documents

Publication Publication Date Title
BR112014009506A2 (pt) composição médica de eperisona estabilizada e preparação estabilizada de liberação sustentada contendo eperisona
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
ECSP21003643A (es) Compuestos antagonistas de pcsk9
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
PE20151890A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
EA201490803A1 (ru) Составы этанерцепта, стабилизированные ксилитом
EA201390339A1 (ru) Замещенные имидазопиридазины
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
NZ743714A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
BR112014025132A2 (pt) formulações de insulina
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
BR112018002115A2 (pt) benzamidas aneladas
BR112013017302A2 (pt) formulações de imunossupressor
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
NZ603465A (en) Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06T Formal requirements before examination
B07A Technical examination (opinion): publication of technical examination (opinion)
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2012, OBSERVADAS AS CONDICOES LEGAIS.